To appraise the clinical and cost-effectiveness of daratumumab in combination with Bortezomib, thalidomide and dexamethasone within its marketing authorisation for multiple myeloma
Status In progress
Process STA 2018
ID number 1510

Provisional Schedule

Committee meeting: 3 04 November 2021
Expected publication 12 January 2022

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton


Companies sponsors Janssen-Cilag (daratumumab, bortezomib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Leukaemia CARE
  Myeloma UK
Professional groups Association of Cancer Physicians
  Cancer research UK
  Royal College of Physicians
  Royal College of Radiologists
  UK Myeloma Forum


Associated public health groups None
Comparator companies Bristol Myers Squibb (BMS)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
26 August 2021 - 17 September 2021 Appraisal consultation: 2
07 July 2021 Committee meeting: 2
27 May 2021 - 18 June 2021 Appraisal consultation
05 May 2021 Committee meeting: 1
30 June 2020 Invitation to participate
11 May 2020 - 09 June 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
08 May 2019 In progress. Referred 21 March 2017
09 January 2019 - 06 February 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
27 April 0202 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable. Following on from information received from the company this appraisal has now been scheduled into the work programme. The appraisal is anticipated to begin during late June 2020 when we will write to you about how you can get involved.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance